Verrica Pharmaceuticals (NASDAQ:VRCA) Announces Earnings Results, Misses Expectations By $0.08 EPS

Verrica Pharmaceuticals (NASDAQ:VRCA) issued its quarterly earnings data on Wednesday. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.08), FiscalAI reports. The business had revenue of $5.09 million during the quarter, compared to analyst estimates of $4.52 million.

Verrica Pharmaceuticals Price Performance

Shares of NASDAQ:VRCA opened at $5.98 on Wednesday. The company has a market capitalization of $95.62 million, a PE ratio of -1.75 and a beta of 1.47. The business has a fifty day moving average price of $6.79 and a two-hundred day moving average price of $5.86. Verrica Pharmaceuticals has a 1 year low of $3.28 and a 1 year high of $9.82.

Analyst Ratings Changes

Several research firms have recently issued reports on VRCA. Brookline Capital Acquisition upgraded shares of Verrica Pharmaceuticals from a “hold” rating to a “buy” rating and set a $17.00 target price for the company in a research note on Thursday, December 18th. TD Cowen reissued a “buy” rating on shares of Verrica Pharmaceuticals in a research report on Wednesday, January 7th. Zacks Research cut shares of Verrica Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday. Wall Street Zen downgraded shares of Verrica Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Finally, Loop Capital set a $17.00 price objective on shares of Verrica Pharmaceuticals in a research note on Thursday, December 18th. Two analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $17.00.

Hedge Funds Weigh In On Verrica Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. OMERS ADMINISTRATION Corp bought a new position in Verrica Pharmaceuticals during the fourth quarter valued at about $188,000. Goldman Sachs Group Inc. purchased a new stake in Verrica Pharmaceuticals during the fourth quarter worth about $155,000. HRT Financial LP bought a new stake in Verrica Pharmaceuticals in the fourth quarter worth about $144,000. XTX Topco Ltd purchased a new position in Verrica Pharmaceuticals in the fourth quarter valued at about $122,000. Finally, Bank of America Corp DE boosted its stake in Verrica Pharmaceuticals by 347.5% in the fourth quarter. Bank of America Corp DE now owns 143,818 shares of the company’s stock valued at $101,000 after acquiring an additional 111,678 shares during the last quarter. 42.45% of the stock is owned by hedge funds and other institutional investors.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of topical therapies for dermatological conditions. Its lead investigational product, VP-102, is a standardized formulation of cantharidin in a pre-measured applicator designed to treat molluscum contagiosum and common warts. Verrica’s approach emphasizes consistency of dosing and patient convenience, aiming to improve upon off‐label use of existing treatments.

Beyond VP-102, Verrica is advancing VP-103, a next‐generation topical candidate intended to optimize tolerability while maintaining efficacy against viral skin lesions.